Spread | 0.05 | ||||
Long position overnight fee Long position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
Overnight fee time | 21:00 (UTC) | ||||
Currency | USD | ||||
Min traded quantity | 1 | ||||
Margin | 20 | ||||
Stock exchange | United States of America | ||||
Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
Prev. Close | 0.78 |
Open | 0.75 |
1-Year Change | -78.32% |
Day's Range | 0.75 - 0.78 |
AlloVir, Inc. is a late clinical-stage cell therapy company. The Company is engaged in developing allogeneic T-cell therapies to treat and prevent viral diseases. Its virus-specific T cell (VST) therapy platform enables to generate VSTs designed to restore immunity in patients with T cell deficiencies. Its product candidate includes Viralym-M (ALVR105), ALVR106, ALVR109, ALVR107 and ALVR108. Its lead product candidate, Viralym-M, is a multi- VST therapy targeting five viruses: BK virus (BKV), cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV), and human herpesvirus 6 (HHV-6). The ALVR106 is an allogeneic VST therapy developed to target diseases caused by four respiratory viruses: respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). Its LVR109 is an allogeneic VST therapy that targets severe acute respiratory syndrome coronavirus two (SARS-CoV-2).
BRIEF: For the fiscal year ended 31 December 2021, Allovir Inc revenues was not reported. Net loss increased from $69.8M to $172M. Higher net loss reflects Research and development increase from $46.1M to $100.1M (expense), Stock-based Compensation in SGA increase from $5.9M to $23.3M (expense), Stock-based Compensation in R&D increase from $3.6M to $20.6M (expense).